Mirum Pharmaceuticals, Inc. has disclosed in a recent SEC filing that director Laura Brege sold 14,167 shares of the company's common stock. The transaction, valued at approximately $1.33 million, occurred on November 11, 2026, following an option exercise.
This sale is significant as it highlights ongoing management activity within the company. As Mirum continues to operate in the competitive pharmaceutical preparations industry, such transactions can indicate confidence in the company's future prospects.
Background
Mirum Pharmaceuticals, Inc. is a company focused on developing and commercializing innovative therapies for patients with rare diseases. The company is classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. Mirum trades on the Nasdaq under the ticker symbol MIRM and is categorized as a large accelerated filer.
What the Filing Says
The SEC filing, dated November 12, 2026, states, "Sales that were executed on November 11, 2026 are being reported on this Form 144 filed on November 12, 2026 given the EDGAR system was not accepting filings on November 11, 2026 in observance of the federal holiday." This filing indicates that the shares sold were part of a stock option exercise.
Impact
This transaction may affect investor perception of Mirum Pharmaceuticals, particularly in how management's actions are viewed in relation to the company's performance and future outlook. Additionally, the sale could influence the trading activity of Mirum's shares on the Nasdaq.
What's Next
The filing does not say what happens next.
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










